24 Apr 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Australian-based CRO, CPR Pharma Services, is launching a service aimed at US-based companies who want access to the Asia Pacific region.
While access to therapeutically naive populations in Asia to conduct late phase studies is not new, CPR is focused on early phase studies, utilising its network of experienced phase I units with access to various ethnicities to address gap in the CRO market for small to medium biotech and pharma.
CPR's Access2Asia service is being launched at the BIO 2013 conference in Chicago, US. Access2Asia is aimed at assisting US based pharmas and biotech in navigating the regulatory minefield by supporting all aspects of conducting trials in Asia.
Because of CPR's extensive network and experience in the region, it has set up Access2Asia, providing US companies with a link to phase I units across Asia. Any selected site is then overlayed with CPRs specialist early phase expertise. CPR provides best practice project management, monitoring, data management, quality assurance, pharmacokinetic, bio-statistical, report writing and bio-analytical support services that constitute a high quality clinical trial package.
According to CPR Pharma Services CEO, Mr Jason Valentine, the service allows US companies to not only access "Western-style high quality clinical trials at a fraction of what it costs in the US or Europe, but also provides access to the booming Asian market." He also said that, "Asia, and particularly China, has a growing middle class that wants access to pharmaceuticals. In order to access this market Western companies need to trial their drugs in the region. CPR can help these US companies navigate the often complex regulatory systems across Asia."